BioGX COVID-19 Tests Detect Omicron SARS-CoV-2 Variant
BioGX’s SARS-CoV-2 surveillance program includes exhaustive in-silico analysis and experimental testing by BioGX scientists using RNA sequences containing the mutations present within the emerging SARS-CoV-2 variants. The analysis conducted by BioGX confirmed the BioGX portfolio of COVID-19 tests maintain detection coverage for all variants of interest and variants of concern, including the new Omicron variant.
BioGX offers a portfolio of COVID-19 RT-PCR tests for a variety of real-time PCR platforms, including BD MAX™ System, Applied Biosystems™ 7500 Fast Dx, Applied Biosystems™ QuantStudio™ 5, Bio-Rad CFX96 Touch™ and Bio-Rad CFX384 Touch™. Details of each test are available at BioGX.com. Within the BioGX portfolio, the Xfree™ COVID-19 Direct RT-PCR is the most popular test because of its ease-of-use and flexibility for high throughput applications. To perform the RT-PCR testing, the user simply rehydrates the lyophilized Xfree™ reagent with molecular grade water, adds the patient sample, and runs the test on a validated real-time PCR instrument. Xfree™ COVID-19 is the only lyophilized, direct sample addition, extraction-free, RT-PCR test to receive FDA emergency use authorization for a variety of widely available real-time PCR instruments and specimen types. Additionally, the test is authorized to run with extracted samples, offering options for the laboratory to adapt the test for any laboratory workflow.
Customers can request information by contacting BioGX at Ph: +1.205.250.8055 or sales@biogx.com.
About BioGX
BioGX is a leading global provider of lyophilized real-time PCR reagents for molecular diagnostics.
For more information on BioGX, please visit BioGX.com.
Sample-Ready, Just Add Water and Xfree are registered or pending trademarks of
BD MAX trademarks are property of
QuantStudio 5 and 7500 Fast Dx are trademarks of
Bio-Rad CFX96 Touch and Bio-Rad CFX384 Touch are trademarks of
View source version on businesswire.com: https://www.businesswire.com/news/home/20211206005557/en/
mohammed.merchant@biogx.com
Source: BioGX